Clinical Trials
27 trialsNCT07431281 2026-05-27
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
AstraZeneca
Phase 3 Recruiting
NCT04379596 2026-05-13
DG-03
AstraZeneca
Phase 2 Recruiting
NCT04864067 2026-05-08
NOAHS-ARC
Servicio de Salud Metropolitano Sur Oriente
Phase 2 Completed
NCT03504397 2026-05-04
Spotlight
Astellas Pharma Inc
Phase 3 Active not recruiting
NCT06846346 2026-04-28
GRACIE
UNICANCER
Phase 2 Recruiting
NCT03777813 2025-11-18
ARION
UNICANCER
Phase 2 Completed
NCT04363801 2025-10-09
DisTinGuish
Leap Therapeutics, Inc.
Phase 2 Terminated
NCT02795988 2025-04-16
A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric Cancer
Imugene Limited
Phase 1/2 Completed
NCT01249352 2025-03-31
NICE
Eurofarma Laboratorios S.A.
Phase 2/3 Completed
NCT02509286 2024-05-08
ESOPEC
University Hospital Schleswig-Holstein
Phase 3 Unknown
NCT04299880 2023-11-08
Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols
Sumitomo Pharma America, Inc.
Phase 1 Completed
NCT05264896 2023-09-07
Perioperative FLOT vs Adjuvant XELOX for CA Stomach
Chinese University of Hong Kong
Phase 3 Recruiting
NCT01726582 2023-08-14
Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine")
Medical College of Wisconsin
Phase 2 Completed
NCT01442935 2021-06-18
Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases
UNICANCER
Phase 2 Completed
NCT01217060 2021-04-13
Trimodality Management of T1b Esophageal Cancers
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT01652976 2021-01-05
FOLFOX-D
University of Florida
Phase 2 Completed
NCT03207724 2020-12-30
OnFX
Cedars-Sinai Medical Center
Phase 1 Completed
NCT00515411 2019-12-10
Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT02620800 2019-10-22
FABLOx
Celgene
Phase 1 Completed
NCT01206530 2019-04-18
FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer
Abramson Cancer Center at Penn Medicine
Phase 1/2 Completed
NCT01383538 2017-08-08
FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma
University of California, San Francisco
Phase 1 Completed
NCT01376453 2016-09-12
Pre-operative 5-Fluorouracil (5-FU) and Sorafenib With External Radiation in Locally Advanced Rectal Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT01932580 2015-10-27
Pilot Study of Perioperative Docetaxel, Oxaliplatin, and 5-Fluorouracil (FLOT) in Gastroesophageal Adenocarcinoma
McGill University
Phase 2 Completed
NCT01554059 2014-11-10
New Beat
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 2 Completed
NCT00368329 2012-07-16
Phase I Dose Escalation of Stereotactic Radiosurgical Boost for Locally Advanced Esophageal Cancer
Stanford University
Phase 1 Terminated
NCT01175291 2011-12-05
FOLFOX/Bevacizumab +/- MK-0646 in Metastatic Colorectal Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Withdrawn
NCT00054873 2006-07-11
Tezacitabine With or Without 5-Fluorouracil (5-FU) for Advanced Esophageal Cancer or Gastric Cancer
Chiron Corporation
Phase 2 Completed